HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PDM-042

a phosphodiesterase 10A inhibitor with antipsychotic activity

Also Known As:

4-(2-(2-(5,8-dimethyl-(1,2,4)triazolo(1,5-a)pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - PDM-042: 2
  - Pyrazines: 150
    - PDM-042: 2

Experts

1.	Arakawa, Keita: 1 article (08/2016)
2.	Ishikawa, Makoto: 1 article (08/2016)
3.	Kato, Yutaka: 1 article (08/2016)
4.	Maehara, Shunsuke: 1 article (08/2016)
5.	Miyazaki, Yutaka: 1 article (08/2016)
6.	Naba, Hiroyasu: 1 article (08/2016)
7.	Nakao, Kazunari: 1 article (08/2016)
8.	Yuge, Natsuko: 1 article (08/2016)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 08/01/2016 - "In behavioral studies using rat models relevant to schizophrenia, PDM-042 significantly antagonized MK-801-induced hyperlocomotion (0.1-0.3 mg/kg) without affecting spontaneous locomotor activity and attenuated the conditioned avoidance response (CAR) (0.3-1 mg/kg). " 08/01/2016 - "Our results suggest that PDM-042 is a good pharmacological tool that can be used to investigate the role of PDE10A and may have therapeutic potential for the treatment of schizophrenia." 08/01/2016 - "Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia."
2.	Dyskinesias (Dyskinesia) 07/30/2022 - "Conversely, the high dose of PDM-042 did not affect peak-dose dyskinesia, prolonged AIMs, and increased cortically evoked spike activity. " 07/30/2022 - "The low dose of PDM-042 had an antidyskinetic effect (i.e., attenuated peak-dose dyskinesia) and did not interfere with cortically evoked spike activity. "
3.	Catalepsy 08/01/2016 - "In tests for adverse effects, PDM-042 had a minimal effect on catalepsy, even at a much higher dose (10 mg/kg) than the minimal effective dose (0.3 mg/kg) in the CAR. "

Related Drugs and Biologics

1.	Phosphoric Diester Hydrolases (Phosphodiesterases)
2.	morpholine